The research on IDH-mutant gliomas and the immunosuppressive mechanisms in the glioma microenvironment will help develop immunotherapy drugs and design new immunotherapies to target potential glioma therapeutic targets and kill tumor cells more efficiently. This evidence concerns the gene IDH2 and neoplasm.